Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment

Area of Science:

• Oncology
• Immunology
• Cancer immunotherapy

Background:

• Immunotherapy, specifically programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade, has transformed cancer treatment.
• However, only a subset of patients achieve durable responses, and some experience relapse, highlighting the need for improved strategies.
• Cytokine therapy has demonstrated efficacy in cancer immunotherapy, suggesting potential synergistic effects when combined with immune checkpoint inhibitors.

Purpose of the Study:

• To review the current knowledge on PD-1/PD-L1 inhibitors and their combination with cytokines.
• To explore the potential benefits of combining anti-PD-1/PD-L1 therapies with various cytokines (e.g., IL-2, IL-15, IL-21, IL-12, IL-10, IFN-α).
• To discuss novel therapeutic approaches for enhancing antitumor immune responses.

Main Methods:

• Literature review of existing studies on PD-1/PD-L1 inhibitors.
• Analysis of data regarding the combination of anti-PD-1/PD-L1 antibodies with different cytokines.
• Synthesis of current knowledge on the efficacy and potential of these combined approaches.

Main Results:

• PD-1/PD-L1 blockade is a revolutionary cancer treatment, but response rates and durability remain a challenge.
• Combinations of PD-1/PD-L1 inhibitors with cytokines show promise for enhancing therapeutic efficacy.
• Specific cytokines like IL-2, IL-15, and IFN-α are being investigated for their synergistic potential with immune checkpoint blockade.

Conclusions:

• Combining recombinant cytokines with PD-1/PD-L1 blockade therapy represents a promising strategy to enhance antitumor immune responses.
• These novel therapeutic approaches may overcome resistance and improve outcomes for a broader range of cancer patients.
• Further research is warranted to optimize these combinations for clinical application.